{"name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","slug":"chia-tai-tianqing-pharmaceutical-group-co-ltd","ticker":"","exchange":"","domain":"chiataitianqing.com","description":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is a leading pharmaceutical company in China with a strong focus on research and development, particularly in oncology. The company has an extensive portfolio of over 225 drugs, including several in late-stage clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":26,"colorKey":"cardiovascular","drugs":[{"name":"Anlotinib hydrochloride capsule + TQB2450 injection","genericName":"Anlotinib hydrochloride capsule + TQB2450 injection","slug":"anlotinib-hydrochloride-capsule-tqb2450-injection","indication":"Advanced non-small cell lung cancer","status":"phase_3"},{"name":"Anlotinib hydrochloride capsules","genericName":"Anlotinib hydrochloride capsules","slug":"anlotinib-hydrochloride-capsules","indication":"Advanced non-small cell lung cancer","status":"marketed"},{"name":"Anlotinib hydrochloride capsules, Penpulimab injection","genericName":"Anlotinib hydrochloride capsules, Penpulimab injection","slug":"anlotinib-hydrochloride-capsules-penpulimab-injection","indication":"Advanced non-small cell lung cancer","status":"phase_3"},{"name":"Docetaxel injection","genericName":"Docetaxel injection","slug":"docetaxel-injection","indication":"Metastatic breast cancer","status":"phase_3"},{"name":"Gemcitabine Hydrochloride Injection","genericName":"Gemcitabine Hydrochloride Injection","slug":"gemcitabine-hydrochloride-injection","indication":"Pancreatic cancer","status":"phase_3"},{"name":"Placebo capsules, Letrozole, Anastrozole, Tamoxifen","genericName":"Placebo capsules, Letrozole, Anastrozole, Tamoxifen","slug":"placebo-capsules-letrozole-anastrozole-tamoxifen","indication":"Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women","status":"phase_3"},{"name":"TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen","genericName":"TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen","slug":"tqb3616-capsules-letrozole-anastrozole-tamoxifen","indication":"Treatment of hormone receptor-positive metastatic breast cancer","status":"phase_3"},{"name":"AL2846 capsules","genericName":"AL2846 capsules","slug":"al2846-capsules","indication":"Oncology indication (specific tumor type not publicly confirmed)","status":"phase_3"},{"name":"Abiraterone acetate tablets","genericName":"Abiraterone acetate tablets","slug":"abiraterone-acetate-tablets","indication":"Prostate cancer","status":"phase_2"},{"name":"Anlotinib(blank)","genericName":"Anlotinib(blank)","slug":"anlotinib-blank","indication":"Advanced non-small cell lung cancer","status":"phase_3"},{"name":"Carboplatin Injection","genericName":"Carboplatin Injection","slug":"carboplatin-injection","indication":"Ovarian cancer","status":"marketed"},{"name":"Dasatinib Tablets","genericName":"Dasatinib Tablets","slug":"dasatinib-tablets","indication":"Chronic myeloid leukemia (CML), chronic phase, accelerated phase, and blast crisis","status":"marketed"},{"name":"Nelarabine injection","genericName":"Nelarabine injection","slug":"nelarabine-injection","indication":"T-cell acute lymphoblastic leukemia (T-ALL)","status":"phase_3"},{"name":"Pemetrexed disodium f Injection","genericName":"Pemetrexed disodium f Injection","slug":"pemetrexed-disodium-f-injection","indication":"Non-small cell lung cancer (NSCLC)","status":"phase_3"},{"name":"Perjeta + Trastuzumab + Docetaxel","genericName":"Perjeta + Trastuzumab + Docetaxel","slug":"perjeta-trastuzumab-docetaxel","indication":"HER2-positive metastatic breast cancer","status":"phase_3"},{"name":"TQ-B3139","genericName":"TQ-B3139","slug":"tq-b3139","indication":"Solid tumors (specific indications under investigation in Phase 3)","status":"phase_3"},{"name":"TQB2303","genericName":"TQB2303","slug":"tqb2303","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"TQB2440 injection + Trastuzumab + Docetaxel","genericName":"TQB2440 injection + Trastuzumab + Docetaxel","slug":"tqb2440-injection-trastuzumab-docetaxel","indication":"Locally advanced or metastatic HER2-positive breast cancer","status":"phase_3"},{"name":"TQB2450(blank)","genericName":"TQB2450(blank)","slug":"tqb2450-blank","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"TQB2450+Anlotinib","genericName":"TQB2450+Anlotinib","slug":"tqb2450-anlotinib","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"TQB3454 Tablets","genericName":"TQB3454 Tablets","slug":"tqb3454-tablets","indication":"Advanced solid tumors","status":"phase_3"},{"name":"TQB3473","genericName":"TQB3473","slug":"tqb3473","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"TQB3616 capsule","genericName":"TQB3616 capsule","slug":"tqb3616-capsule","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"TQB3616 capsules","genericName":"TQB3616 capsules","slug":"tqb3616-capsules","indication":"Advanced or metastatic solid tumors with FGFR alterations (in development)","status":"phase_3"},{"name":"TQZ2451","genericName":"TQZ2451","slug":"tqz2451","indication":"Metastatic non-small cell lung cancer","status":"phase_3"},{"name":"Toripalimab injection","genericName":"Toripalimab injection","slug":"toripalimab-injection","indication":"Melanoma","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":15,"colorKey":"immunology","drugs":[{"name":"TQB3473 Tablets","genericName":"TQB3473 Tablets","slug":"tqb3473-tablets","indication":"Other","status":"phase_3"},{"name":"Entecavir Tablet","genericName":"Entecavir Tablet","slug":"entecavir-tablet","indication":"Other","status":"marketed"},{"name":"Faropenem（low-dose group)","genericName":"Faropenem（low-dose group)","slug":"faropenem-low-dose-group","indication":"Other","status":"phase_2"},{"name":"TQ-B3233","genericName":"TQ-B3233","slug":"tq-b3233","indication":"Other","status":"phase_1"},{"name":"TQD3524","genericName":"TQD3524","slug":"tqd3524","indication":"Other","status":"phase_1"},{"name":"Angiotensin II Injection","genericName":"Angiotensin II Injection","slug":"angiotensin-ii-injection","indication":"Distributive shock (septic shock) with hypotension refractory to catecholamines","status":"phase_3"},{"name":"Gemzar","genericName":"Gemzar","slug":"gemzar","indication":"Other","status":"phase_3"},{"name":"L-pantoprazole sodium","genericName":"L-pantoprazole sodium","slug":"l-pantoprazole-sodium","indication":"Other","status":"phase_1"},{"name":"Obeticholic Acid Tablets","genericName":"Obeticholic Acid Tablets","slug":"obeticholic-acid-tablets","indication":"Other","status":"marketed"},{"name":"Panmeilu","genericName":"Panmeilu","slug":"panmeilu","indication":"Other","status":"phase_1"},{"name":"Sinotecean","genericName":"Sinotecean","slug":"sinotecean","indication":"Other","status":"phase_1"},{"name":"Spiriva®Handihaler®","genericName":"Spiriva®Handihaler®","slug":"spirivahandihaler","indication":"Other","status":"marketed"},{"name":"TQ-B3234 capsules","genericName":"TQ-B3234 capsules","slug":"tq-b3234-capsules","indication":"Other","status":"phase_3"},{"name":"TQB6411 for Injection","genericName":"TQB6411 for Injection","slug":"tqb6411-for-injection","indication":"Other","status":"phase_1"},{"name":"TQH2722 injection 600mg-300mg","genericName":"TQH2722 injection 600mg-300mg","slug":"tqh2722-injection-600mg-300mg","indication":"Other","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"neuroscience","drugs":[{"name":"Meropenem for Injection","genericName":"Meropenem for Injection","slug":"meropenem-for-injection","indication":"Serious bacterial infections including intra-abdominal infections","status":"phase_3"},{"name":"Baraclude tablets","genericName":"Baraclude tablets","slug":"baraclude-tablets","indication":"Chronic hepatitis B infection in adults","status":"marketed"},{"name":"Blank maleate entecavir tablets","genericName":"Blank maleate entecavir tablets","slug":"blank-maleate-entecavir-tablets","indication":"Chronic hepatitis B infection","status":"marketed"},{"name":"Colistimethate sodium for injection","genericName":"Colistimethate sodium for injection","slug":"colistimethate-sodium-for-injection","indication":"Infections caused by multidrug-resistant gram-negative bacteria (e.g., Pseudomonas aeruginosa, Acinetobacter baumannii)","status":"phase_3"},{"name":"Coly Mycin M Injectable Product","genericName":"Coly Mycin M Injectable Product","slug":"coly-mycin-m-injectable-product","indication":"Multidrug-resistant gram-negative bacterial infections (Pseudomonas aeruginosa, Acinetobacter baumannii)","status":"phase_3"},{"name":"Entecavir dispersible tablets","genericName":"Entecavir dispersible tablets","slug":"entecavir-dispersible-tablets","indication":"Chronic hepatitis B","status":"phase_2"},{"name":"blank Baraclude tablets","genericName":"blank Baraclude tablets","slug":"blank-baraclude-tablets","indication":"Chronic hepatitis B infection in adults","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"TQ-B211","genericName":"TQ-B211","slug":"tq-b211","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Tresiba®","genericName":"Tresiba®","slug":"tresiba","indication":"Type 1 diabetes mellitus","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"TQC3721 suspension for inhalation","genericName":"TQC3721 suspension for inhalation","slug":"tqc3721-suspension-for-inhalation","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"},{"name":"Spiriva HandiHaler","genericName":"Spiriva HandiHaler","slug":"spiriva-handihaler","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Fluvestrin injection","genericName":"Fluvestrin injection","slug":"fluvestrin-injection","indication":"Acute myocardial infarction","status":"phase_3"}]}],"pipeline":[{"name":"Fluvestrin injection","genericName":"Fluvestrin injection","slug":"fluvestrin-injection","phase":"phase_3","mechanism":"Fluvestrin is a recombinant human vascular endothelial growth factor (VEGF) that promotes angiogenesis and improves blood flow to ischemic tissues.","indications":["Acute myocardial infarction","Chronic heart failure with reduced ejection fraction"],"catalyst":""},{"name":"TQB3473 Tablets","genericName":"TQB3473 Tablets","slug":"tqb3473-tablets","phase":"phase_3","mechanism":"TQB3473 Tablets' mechanism of action is not publicly available.","indications":[],"catalyst":""},{"name":"Anlotinib hydrochloride capsule + TQB2450 injection","genericName":"Anlotinib hydrochloride capsule + TQB2450 injection","slug":"anlotinib-hydrochloride-capsule-tqb2450-injection","phase":"phase_3","mechanism":"Anlotinib is a multi-target tyrosine kinase inhibitor combined with TQB2450, a PD-L1 inhibitor, to block tumor angiogenesis and enhance anti-tumor immune response.","indications":["Advanced non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"Anlotinib hydrochloride capsules","genericName":"Anlotinib hydrochloride capsules","slug":"anlotinib-hydrochloride-capsules","phase":"marketed","mechanism":"Anlotinib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor growth by inhibiting VEGFR, FGFR, PDGFR, and other kinases.","indications":["Advanced non-small cell lung cancer","Soft tissue sarcoma","Medullary thyroid cancer"],"catalyst":""},{"name":"Anlotinib hydrochloride capsules, Penpulimab injection","genericName":"Anlotinib hydrochloride capsules, Penpulimab injection","slug":"anlotinib-hydrochloride-capsules-penpulimab-injection","phase":"phase_3","mechanism":"Anlotinib is a multi-target tyrosine kinase inhibitor that blocks angiogenesis and tumor growth, while Penpulimab is a PD-1 inhibitor that enhances anti-tumor immune response.","indications":["Advanced non-small cell lung cancer","Other solid tumors (phase 3 evaluation)"],"catalyst":""},{"name":"Docetaxel injection","genericName":"Docetaxel injection","slug":"docetaxel-injection","phase":"phase_3","mechanism":"Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","indications":["Metastatic breast cancer","Non-small cell lung cancer","Prostate cancer","Gastric cancer","Head and neck cancer"],"catalyst":""},{"name":"Entecavir Tablet","genericName":"Entecavir Tablet","slug":"entecavir-tablet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Faropenem（low-dose group)","genericName":"Faropenem（low-dose group)","slug":"faropenem-low-dose-group","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Gemcitabine Hydrochloride Injection","genericName":"Gemcitabine Hydrochloride Injection","slug":"gemcitabine-hydrochloride-injection","phase":"phase_3","mechanism":"Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cell death.","indications":["Pancreatic cancer","Non-small cell lung cancer","Breast cancer","Ovarian cancer","Bladder cancer"],"catalyst":""},{"name":"Meropenem for Injection","genericName":"Meropenem for Injection","slug":"meropenem-for-injection","phase":"phase_3","mechanism":"Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","indications":["Serious bacterial infections including intra-abdominal infections","Meningitis","Nosocomial pneumonia","Febrile neutropenia"],"catalyst":""},{"name":"Placebo capsules, Letrozole, Anastrozole, Tamoxifen","genericName":"Placebo capsules, Letrozole, Anastrozole, Tamoxifen","slug":"placebo-capsules-letrozole-anastrozole-tamoxifen","phase":"phase_3","mechanism":"Letrozole and Anastrozole are aromatase inhibitors, which block the production of estrogen in the body. Tamoxifen is a selective estrogen receptor modulator (SERM), which blocks estrogen receptors in breast tissue.","indications":["Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women","Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women"],"catalyst":""},{"name":"TQ-B211","genericName":"TQ-B211","slug":"tq-b211","phase":"phase_3","mechanism":"TQ-B211 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TQ-B3233","genericName":"TQ-B3233","slug":"tq-b3233","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen","genericName":"TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen","slug":"tqb3616-capsules-letrozole-anastrozole-tamoxifen","phase":"phase_3","mechanism":"Letrozole and Anastrozole are non-steroidal, selective aromatase inhibitors, while Tamoxifen is a selective estrogen receptor modulator.","indications":["Treatment of hormone receptor-positive metastatic breast cancer","Adjuvant treatment of hormone receptor-positive breast cancer"],"catalyst":""},{"name":"TQC3721 suspension for inhalation","genericName":"TQC3721 suspension for inhalation","slug":"tqc3721-suspension-for-inhalation","phase":"phase_3","mechanism":"TQC3721 suspension for inhalation is a medication that targets the respiratory system to treat a specific condition.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"TQD3524","genericName":"TQD3524","slug":"tqd3524","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AL2846 capsules","genericName":"AL2846 capsules","slug":"al2846-capsules","phase":"phase_3","mechanism":"AL2846 is a small-molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival.","indications":["Oncology indication (specific tumor type not publicly confirmed)"],"catalyst":""},{"name":"Abiraterone acetate tablets","genericName":"Abiraterone acetate tablets","slug":"abiraterone-acetate-tablets","phase":"phase_2","mechanism":"CYP17 inhibitor","indications":["Prostate cancer"],"catalyst":""},{"name":"Angiotensin II Injection","genericName":"Angiotensin II Injection","slug":"angiotensin-ii-injection","phase":"phase_3","mechanism":"Angiotensin II is a vasoactive peptide that binds to angiotensin II receptors to increase blood pressure and restore vascular tone in patients with hypotension.","indications":["Distributive shock (septic shock) with hypotension refractory to catecholamines","Severe hypotension in critically ill patients"],"catalyst":""},{"name":"Anlotinib(blank)","genericName":"Anlotinib(blank)","slug":"anlotinib-blank","phase":"phase_3","mechanism":"Anlotinib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor growth by inhibiting VEGFR, FGFR, PDGFR, and other kinases.","indications":["Advanced non-small cell lung cancer","Medullary thyroid cancer","Soft tissue sarcoma"],"catalyst":""},{"name":"Baraclude tablets","genericName":"Baraclude tablets","slug":"baraclude-tablets","phase":"marketed","mechanism":"Baraclude (entecavir) inhibits hepatitis B virus reverse transcriptase, blocking viral replication.","indications":["Chronic hepatitis B infection in adults","Chronic hepatitis B infection in children and adolescents"],"catalyst":""},{"name":"Blank maleate entecavir tablets","genericName":"Blank maleate entecavir tablets","slug":"blank-maleate-entecavir-tablets","phase":"marketed","mechanism":"Entecavir inhibits hepatitis B virus reverse transcriptase and protein priming, blocking viral DNA replication.","indications":["Chronic hepatitis B infection","Hepatitis B with compensated liver disease","Hepatitis B with decompensated liver disease"],"catalyst":""},{"name":"Carboplatin Injection","genericName":"Carboplatin Injection","slug":"carboplatin-injection","phase":"marketed","mechanism":"Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing apoptosis.","indications":["Ovarian cancer","Lung cancer","Breast cancer","Head and neck cancer","Testicular cancer"],"catalyst":""},{"name":"Colistimethate sodium for injection","genericName":"Colistimethate sodium for injection","slug":"colistimethate-sodium-for-injection","phase":"phase_3","mechanism":"Colistimethate sodium is a prodrug of colistin that disrupts bacterial cell membranes by binding to lipopolysaccharides and phospholipids, leading to cell lysis and death.","indications":["Infections caused by multidrug-resistant gram-negative bacteria (e.g., Pseudomonas aeruginosa, Acinetobacter baumannii)","Hospital-acquired pneumonia and other serious infections in patients with limited treatment options"],"catalyst":""},{"name":"Coly Mycin M Injectable Product","genericName":"Coly Mycin M Injectable Product","slug":"coly-mycin-m-injectable-product","phase":"phase_3","mechanism":"Colistin (polymyxin E) is a cyclic polypeptide antibiotic that disrupts bacterial cell membranes by binding to lipopolysaccharides and phospholipids, leading to cell lysis and death.","indications":["Multidrug-resistant gram-negative bacterial infections (Pseudomonas aeruginosa, Acinetobacter baumannii)","Serious infections in hospitalized patients unresponsive to other antibiotics"],"catalyst":""},{"name":"Dasatinib Tablets","genericName":"Dasatinib Tablets","slug":"dasatinib-tablets","phase":"marketed","mechanism":"Dasatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and multiple other kinases involved in cancer cell proliferation and survival.","indications":["Chronic myeloid leukemia (CML), chronic phase, accelerated phase, and blast crisis","Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)"],"catalyst":""},{"name":"Entecavir dispersible tablets","genericName":"Entecavir dispersible tablets","slug":"entecavir-dispersible-tablets","phase":"phase_2","mechanism":"Inhibits hepatitis B virus DNA polymerase","indications":["Chronic hepatitis B"],"catalyst":""},{"name":"Gemzar","genericName":"Gemzar","slug":"gemzar","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"L-pantoprazole sodium","genericName":"L-pantoprazole sodium","slug":"l-pantoprazole-sodium","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nelarabine injection","genericName":"Nelarabine injection","slug":"nelarabine-injection","phase":"phase_3","mechanism":"Nelarabine is a prodrug that is converted to arabinosyl guanine, which inhibits ribonucleotide reductase and DNA synthesis, leading to apoptosis in T-cell malignancies.","indications":["T-cell acute lymphoblastic leukemia (T-ALL)","T-cell lymphoblastic lymphoma (T-LBL)"],"catalyst":""},{"name":"Obeticholic Acid Tablets","genericName":"Obeticholic Acid Tablets","slug":"obeticholic-acid-tablets","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Panmeilu","genericName":"Panmeilu","slug":"panmeilu","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pemetrexed disodium f Injection","genericName":"Pemetrexed disodium f Injection","slug":"pemetrexed-disodium-f-injection","phase":"phase_3","mechanism":"Pemetrexed is a folate antagonist that inhibits multiple enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells.","indications":["Non-small cell lung cancer (NSCLC)","Mesothelioma","Colorectal cancer"],"catalyst":""},{"name":"Perjeta + Trastuzumab + Docetaxel","genericName":"Perjeta + Trastuzumab + Docetaxel","slug":"perjeta-trastuzumab-docetaxel","phase":"phase_3","mechanism":"This combination uses two HER2-targeting monoclonal antibodies (Perjeta and Trastuzumab) plus a taxane chemotherapy to block HER2 signaling and inhibit microtubule dynamics in HER2-positive breast cancer cells.","indications":["HER2-positive metastatic breast cancer","HER2-positive early-stage breast cancer (neoadjuvant/adjuvant setting)"],"catalyst":""},{"name":"Sinotecean","genericName":"Sinotecean","slug":"sinotecean","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Spiriva HandiHaler","genericName":"Spiriva HandiHaler","slug":"spiriva-handihaler","phase":"marketed","mechanism":"Spiriva HandiHaler delivers tiotropium, a long-acting anticholinergic agent that blocks muscarinic receptors in airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment","Asthma maintenance treatment"],"catalyst":""},{"name":"Spiriva®Handihaler®","genericName":"Spiriva®Handihaler®","slug":"spirivahandihaler","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TQ-B3139","genericName":"TQ-B3139","slug":"tq-b3139","phase":"phase_3","mechanism":"TQ-B3139 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and survival.","indications":["Solid tumors (specific indications under investigation in Phase 3)"],"catalyst":""},{"name":"TQ-B3234 capsules","genericName":"TQ-B3234 capsules","slug":"tq-b3234-capsules","phase":"phase_3","mechanism":"TQ-B3234 capsules' mechanism is not publicly available.","indications":[],"catalyst":""},{"name":"TQB2303","genericName":"TQB2303","slug":"tqb2303","phase":"phase_3","mechanism":"TQB2303 is a small molecule targeting the PD-1/PD-L1 pathway.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"TQB2440 injection + Trastuzumab + Docetaxel","genericName":"TQB2440 injection + Trastuzumab + Docetaxel","slug":"tqb2440-injection-trastuzumab-docetaxel","phase":"phase_3","mechanism":"TQB2440 injection is a targeted therapy that works by inhibiting the PD-1/PD-L1 pathway, while Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor, and Docetaxel is a chemotherapy medication that works by inhibiting cell division.","indications":["Locally advanced or metastatic HER2-positive breast cancer","Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma"],"catalyst":""},{"name":"TQB2450(blank)","genericName":"TQB2450(blank)","slug":"tqb2450-blank","phase":"phase_3","mechanism":"TQB2450 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"TQB2450+Anlotinib","genericName":"TQB2450+Anlotinib","slug":"tqb2450-anlotinib","phase":"phase_3","mechanism":"TQB2450 is a tyrosine kinase inhibitor, and Anlotinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor.","indications":["Non-small cell lung cancer","Gastric cancer"],"catalyst":""},{"name":"TQB3454 Tablets","genericName":"TQB3454 Tablets","slug":"tqb3454-tablets","phase":"phase_3","mechanism":"TQB3454 is designed to inhibit the activity of a specific enzyme involved in the progression of certain cancers.","indications":["Advanced solid tumors"],"catalyst":""},{"name":"TQB3473","genericName":"TQB3473","slug":"tqb3473","phase":"phase_3","mechanism":"TQB3473 is a small molecule drug that targets the PD-1/PD-L1 pathway.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"TQB3616 capsule","genericName":"TQB3616 capsule","slug":"tqb3616-capsule","phase":"phase_3","mechanism":"TQB3616 capsule is a small molecule drug that targets the PD-1/PD-L1 pathway.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"TQB3616 capsules","genericName":"TQB3616 capsules","slug":"tqb3616-capsules","phase":"phase_3","mechanism":"TQB3616 is a small-molecule inhibitor that targets fibroblast growth factor receptor (FGFR) signaling pathways.","indications":["Advanced or metastatic solid tumors with FGFR alterations (in development)"],"catalyst":""},{"name":"TQB6411 for Injection","genericName":"TQB6411 for Injection","slug":"tqb6411-for-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TQH2722 injection 600mg-300mg","genericName":"TQH2722 injection 600mg-300mg","slug":"tqh2722-injection-600mg-300mg","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TQZ2451","genericName":"TQZ2451","slug":"tqz2451","phase":"phase_3","mechanism":"TQZ2451 is a small molecule drug that targets the molecular target.","indications":["Metastatic non-small cell lung cancer"],"catalyst":""},{"name":"Toripalimab injection","genericName":"Toripalimab injection","slug":"toripalimab-injection","phase":"phase_3","mechanism":"Toripalimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.","indications":["Melanoma","Non-small cell lung cancer","Nasopharyngeal carcinoma","Esophageal squamous cell carcinoma"],"catalyst":""},{"name":"Tresiba®","genericName":"Tresiba®","slug":"tresiba","phase":"marketed","mechanism":"Tresiba is a long-acting basal insulin analog that binds to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"blank Baraclude tablets","genericName":"blank Baraclude tablets","slug":"blank-baraclude-tablets","phase":"marketed","mechanism":"Baraclude (entecavir) inhibits hepatitis B virus reverse transcriptase, blocking viral replication.","indications":["Chronic hepatitis B infection in adults","Chronic hepatitis B infection in children and adolescents"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxQczFaMW1rekJaNmo3bVNnMEJQUmJkSWxPa0tQYmt0T2I3TW5CY1F3VmQ0eWpKcjZDOWVpMnNFQjFkd01ZSkQwRTI4TDRjTF9KMS1VRFNoODBObDE3elJaVTVZN1lvRmMtVl9COU1LX3dZRFlCSkdfcDYxVzNza1dWSU1ZbUoyUlRyZUt6TVZLVTRHYjhhYnozNG91TzhpTUxoVVhUNjlER0huVGFSV3ctb2gtMWE1NU4wSEhBWkJLbkk1amtmbFhVS09UcVF6QXNQR1dFQmczRDhZZENrUVJRVlVPVDNLaDVqZkJ3R2Vvbi1EYjk2R1dyVU1VQkctaTBKM0EycmZPNXVRQnJ3OWpzVFRrUW0wVWxFdWdqLUhhUUtyV0lsSUdHVmh4MS1XMUJTLS02SzJUWl8xdmYwSDE4?oc=5","date":"2026-04-01","type":"regulatory","source":"globenewswire.com","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline - globenewswire.com","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPZDg1Z01CSUR6V0pPTkdnYmFaNEE3NzA1US03VWZJLTg3Y05FTWVpZ0MwS2xaVEFhSXFLMElZbmtrdzUxbEpFTHdiNzBKZDN6enJiZWdLV2tNQjRPaU5qcVJmN0luRlFFNEF1R01nWXVreTl5SUszaDgtNkVtcUx5WFhzUkcyeWk2M1ZrRWUxcERobWZVOTkxTmdadi05Zw?oc=5","date":"2026-03-11","type":"trial","source":"openPR.com","summary":"Advanced Liver Cancer Clinical Trial Pipeline Shows Potential - openPR.com","headline":"Advanced Liver Cancer Clinical Trial Pipeline Shows Potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOUVpfcDNiUGZnelozQmZqTjd6aGxPZXBKa2s0cHVQa055WUthRGJab2pzTVZqVjNhLUxhQUJocmZLQVF6aVNtNXJJR1pXeWRhTEp1NkhqYVpXenBMMkViN3pYd3E5OEJ0SEpXM3ktaUFYZE9Wd3YyX0llSGhKNmhCX3phZ2NmUWpBYVNYZjQ5OGhQLWh5Y0RsQnFJUnM0enZFWTlTYkhUS0NLendHclJvRERn?oc=5","date":"2026-03-04","type":"deal","source":"Fierce Pharma","summary":"Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset - Fierce Pharma","headline":"Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxPNTlrMzJLMTUyX3RKRzJWYi1UX1RvSlZ2RUNEd2EtcDJmemhHLUlFZXQxSjcza29rTE9kUFRwRUN2ckdQS0tMcHhfUEN1VDUxeHZMQ1A4NWtqeUYwSFBpM1Y5ZUo3U1NqSk9nM2NtQXBwMDg0R2k3a2U4VTVkSktvR1pxVW8zdS1pQUZ5aExHU3dtY3Y3MTUyVmt2NzVITFBQUktxdHVORlM5WDFTcGZGYkJvM3pNc1ByYTFQT1ZNOUZBYkp6elFBbzNqT3RUQXBNU0FVYWoyemFGRUdUajJjTzlZX2kxX0phc1d2M0xoa1g5TWtvT1N0NVBWY2pZcERNd3N2ck5UV3FWU0MxUWtCbnd3?oc=5","date":"2026-02-16","type":"pipeline","source":"PR Newswire UK","summary":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight - PR Newswire UK","headline":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQTFF5S0N3MDEyeGg3bUQ1UGNJa3BpeDN6aDJhckpERDNyTnJvSEJSX2o5cGtQREJGUllIY2dma0ozMDJla2ZWTUNQQ0lIelZDVFRJZXVqMjNMWWVQVDZ0cE9aM1JLckRNYW0yM0NOSjJ5aVpRbXZvSS1Rd2ZsdjRxdkx1anAtaVVSSXhSaUhpRGJoNFBHWlhoLUVub195WW01UTVDT3o1eGhQakx5bTVWckwyUk9kX2tydmNBa0Utd3JNZGJiTV9OU3NwdE9zblZ2RjhGVGtOc3dWX0pYaWZRTnc0WDdCZUk?oc=5","date":"2025-08-29","type":"regulatory","source":"businesswireindia.com","summary":"Novotech Supports Groundbreaking Approval of Anlotinib Combination Therapy for Advanced Soft Tissue Sarcoma - businesswireindia.com","headline":"Novotech Supports Groundbreaking Approval of Anlotinib Combination Therapy for Advanced Soft Tissue Sarcoma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQLUdGNExlVk1Yb25WMVhZWUlQUzgteV93WGRaSHU4WWZzMDFUYURLQXV5dFdHM3JTcERzSVQ5eUlLOFRSTXFsak8xdFJ4RmpHblB6YXJWY0tXMnhrQWluUk5OTkRqWTZvWHB0UkUyMndISW9XSS1tNDhnTDVnZmVxZm1lWUVLM3VVb2Y0dzJ2ZDExNWlhNk84RERxRkJSY2RubzhfSHZPZ3JpQ1NhSWV3ODltTlc3TF9ZWlV4LXFNWV9EdFlOT1RQNnFGeVotT3l3LWhmd2Z1Y19DcmtfQzJqdDlSaFlsZWJhWmlPMVluVkIzTmRPcTQxcDZ1UkhicGVfQUFqZ3QtZHVfTEQ1RXB4UmFkVkRmeXduUU1XQzM2YU5Jb002cnNpb01B?oc=5","date":"2024-11-28","type":"trial","source":"PR Newswire","summary":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"PR Newswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - PR Newswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQbGl2VE0yR1dLRXdpTnJIcC12REhSbnhaRDBsc25uNFBnNkYteF82MXU4emdNLTFFVzlIQWExVG1ocXkzZlRsbFlibE81Y1JoejU5ei1EMFJDYjlLSEwydlEtRmFBTk1YRnhGdl9Wc2FzT3hkcHVNTFJTaWQ5ZU9zS0dhUFNJOU9hX0I1TVB5VEZib3ZhaDg3RS1EcnhjSXpnZmgyeA?oc=5","date":"2024-11-13","type":"deal","source":"BioWorld News","summary":"Apollo signs near-$1B deal for Sunshine’s FGF21/GLP-1 injection - BioWorld News","headline":"Apollo signs near-$1B deal for Sunshine’s FGF21/GLP-1 injection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQR0FlZVdKcWI5ODlyTnhNUnFaOWlNeFVtcWpQN2RjNlkwX3dXVnl6SWdrUWhycXBNd0UxNVBLMTk4aXotVmVlenBDSlItUE9Fd0dXa01pdS1sZm1ONDNjaWsxeWZiQzRibmh3QjR6ZC1VaUdoOWVxTDFURl9tdUJ6MlBlRVFURHp2UnBoM1ZSckw3LV8wcjF3ZFRwdHJHaGplOTViamkxamlYQQ?oc=5","date":"2024-09-23","type":"pipeline","source":"Citeline News & Insights","summary":"BIOSECURE Act: Pfizer To Lilly - Where Are The Likely Sourcing Gaps? - Citeline News & Insights","headline":"BIOSECURE Act: Pfizer To Lilly - Where Are The Likely Sourcing Gaps? - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQYnpwb1JyN1dPUzU4b1JYc0JyeTFBZzd5ZVR5ZUU4Y3k0cTJQd2hxV1RjZ1pTRjZjRGxtdi13Q1FBUmtOM2JOaE9NRUVsWGU3VzNMT1N3Mm1sdklCRWZmV2JINFRiMWhCWXdKNTZ0VlZUS2JXOE1ERXRSenNfeHFSbS1JR0c?oc=5","date":"2024-06-06","type":"pipeline","source":"Reuters","summary":"Chia Tai Tianqing Pharmaceutical Group Co Ltd - Reuters","headline":"Chia Tai Tianqing Pharmaceutical Group Co Ltd","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxQTThpN19XbmNnRS16enZMMG5KZUhBbktkMVBsNGE0R0h4a2ZhbzQwQmRiQVJ5Z3JORUhrSlQwRlBuaV9Lc0RJV25ONTlmblBoYjdhaUhwU3JyMHMzOVcxRzZtRE9PZjh5YVZueU5PbEVZRWFpamNOZjVpYkd3MTBfc0xwbEN6VzBCUHVrOVczLWRhQWsxbUxWWkRXZWdKVS1fcFBJQWdMRXluWnVHNjdXT1UzMTNWVWVCN3RsV2M3TFZSLWZpZndZcHFVZG5xSHg5My12RHM4N1k2XzBmc3FaQ2Rnc1liTC1hRFJ5SVR5cHI?oc=5","date":"2023-08-22","type":"deal","source":"Business Wire","summary":"Techdow USA and CTTQ Pharma Announce Collaboration Agreement and Launch of Fosaprepitant for Injection - Business Wire","headline":"Techdow USA and CTTQ Pharma Announce Collaboration Agreement and Launch of Fosaprepitant for Injection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFBZZW94Q0ZCZnVsbnRXQnl6bDF3M3ViQUJGdWEzX3V1WURheUVnWTVWOUY5OUhVdjl4anJjQkQ0WXBTak5HLVBsbWtoTnFobXBxWm1xQms3MWV1aGxubml0TTV2R1RFY2ZKbUpLMkdPTHVBNmMzWTJwSw?oc=5","date":"2022-07-28","type":"pipeline","source":"BioCentury","summary":"CEO Li Yi resigns from Sino - BioCentury","headline":"CEO Li Yi resigns from Sino","sentiment":"neutral"}],"patents":[],"drugCount":53,"phaseCounts":{"phase_3":32,"marketed":11,"phase_2":4,"phase_1":6},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}